You are interested in cell-size regulation and discover that signaling through a GPCR called ERC1 is important in controlling cell size in embryonic rat cells. The G protein downstream of ERC1 activates adenylyl cyclase, which ultimately leads to the activation of PKA. You discover that cells that lack ERC1 are 15% smaller than normal cells, while cells that express a mutant, constitutively activated version of PKA are 15% larger than normal cells. Given these results, which of the following treatments to embryonic rat cells should lead to smaller cells?
(a) addition of a drug that causes cyclic AMP phosphodiesterase to be hyperactive
(b) addition of a drug that prevents GTP hydrolysis by Ga
(c) addition of a drug that activates adenylyl cyclase
(d) addition of a drug that mimics the ligand of ERC1
Answer:
If the answers is incorrect or not given, you can answer the above question in the comment box. If the answers is incorrect or not given, you can answer the above question in the comment box.